Revance Therapeutics’ (RVNC) Hold Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report report published on Friday morning,Benzinga reports.

Several other analysts have also commented on the company. Guggenheim reaffirmed a “neutral” rating on shares of Revance Therapeutics in a report on Monday, August 12th. Barclays reiterated an “equal weight” rating and issued a $7.00 target price (down from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Piper Sandler lowered shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 12th. HC Wainwright reiterated a “neutral” rating and issued a $6.60 price objective on shares of Revance Therapeutics in a research report on Friday. Finally, William Blair restated a “market perform” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Revance Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $9.66.

Revance Therapeutics Price Performance

RVNC traded down $2.08 during trading on Friday, reaching $3.70. 13,145,829 shares of the company’s stock were exchanged, compared to its average volume of 2,753,991. The company’s fifty day simple moving average is $5.66 and its 200-day simple moving average is $4.42. The stock has a market capitalization of $387.85 million, a P/E ratio of -1.92 and a beta of 0.95. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.12. The business had revenue of $65.39 million during the quarter, compared to analysts’ expectations of $66.30 million. Revance Therapeutics’s revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.80) earnings per share. Equities analysts forecast that Revance Therapeutics will post -1.53 EPS for the current year.

Institutional Investors Weigh In On Revance Therapeutics

Institutional investors have recently bought and sold shares of the company. Certuity LLC acquired a new position in Revance Therapeutics in the 2nd quarter valued at $26,000. Creative Planning purchased a new position in shares of Revance Therapeutics in the third quarter worth about $56,000. Vanguard Personalized Indexing Management LLC acquired a new position in Revance Therapeutics during the second quarter worth about $33,000. Accredited Investors Inc. purchased a new stake in Revance Therapeutics during the 3rd quarter valued at about $67,000. Finally, Hsbc Holdings PLC purchased a new position in Revance Therapeutics in the 2nd quarter worth approximately $38,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.